<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02633826</url>
  </required_header>
  <id_info>
    <org_study_id>Pre-formed alloreactivity</org_study_id>
    <nct_id>NCT02633826</nct_id>
  </id_info>
  <brief_title>Pre-formed Alloreactivity in Renal Transplant Recipients</brief_title>
  <official_title>The Role of Pre-formed Alloreactive T Cells on Acute Rejection Episodes and Long-term Graft Outcome in Patients After Living Donor Renal Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Martina Sester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Saarland University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This investigator-initiated study will analyse the role of pre-formed alloreactive T cells on
      acute rejection episodes and graft outcome in kidney transplant recipients after living
      donation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In recipients of solid organ transplants, preformed alloreactive T cells may mediate acute
      rejections and compromise long-term graft survival. Previous studies on the role of
      alloreactive T cells in transplantation were hampered by the fact that experimental assays to
      quantify alloreactivity were technically demanding and not suitable for use in a clinical
      setting. Based on a recent development of a whole-blood assay, alloreactive T cells may be
      quantified and characterised within one day. This assay therefore provides the experimental
      basis to study the development and the role of alloreactive T cells in a clinical setting in
      patients after renal transplantation. This will be performed in a multicenter study in living
      donor renal transplant recipients where preformed alloreactivity of the recipient towards the
      living donor will be determined and associated with standard clinical parameters of graft
      function and long-term graft outcome on follow-up. In addition, the development of
      donor-specific antibodies will be analysed after transplantation. If this project was able to
      provide evidence for a role of alloreactive T cells in acute rejection episodes or long-term
      graft function, this assay may in future be used to guide individualized immunosuppressive
      drug treatment early after transplantation. It will thereby aid in distinguishing patients
      where standard immunosuppressive drug regimens are sufficient from the minor population of
      patients at high risk for rejection who will benefit from intensified drug regimens.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>graft function</measure>
    <time_frame>1 year</time_frame>
    <description>1-year graft function (estimated glomerular filtration rate)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Creatinine</measure>
    <time_frame>1 year</time_frame>
    <description>1-year creatinine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cystatin C</measure>
    <time_frame>1 year</time_frame>
    <description>1-year cystatin C</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rejection: acute rejection episodes within the first year</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>proteinuria within the first year</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Kidney Transplantation</condition>
  <condition>Acute Graft Rejection</condition>
  <arm_group>
    <arm_group_label>kidney transplant recipients</arm_group_label>
    <description>kidney transplant recipients of an allograft from a living donor, no intervention</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Transplant recipients of a kidney from a living donor
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent

          -  First or second renal transplantation

          -  Living donor renal transplantation

          -  Recipient older than 18 years

          -  Negative cross match

          -  Planed quadruple, Tacrolimus-based (low-dose) immunosuppressive drug regimen
             (Tacrolimus, 2g MMF starting dose, (methyl)prednisolone according to center practice,
             basiliximab at day 0 and day 4)

          -  Planned start of Tacrolimus (Advagraf®) 3 to 10 days prior to transplantation (trough
             levels 5-10 ng/ml during the first 3 months, 5-7 ng/ml thereafter)

        Exclusion Criteria:

          -  Planed T-cell depleting induction therapy

          -  Pregnancy

          -  Pre-existing, moderate to high dose immunosuppressive medication

          -  Pre-existing, severe lymphopenia (&lt; 400/µl)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Martina Sester, PhD</last_name>
    <phone>0049-6841-16</phone>
    <phone_ext>23557</phone_ext>
    <email>martina.sester@uks.eu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Urban Sester, MD</last_name>
    <phone>0049-6841-16</phone>
    <phone_ext>23541</phone_ext>
    <email>urban.sester@uks.eu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Saarland University</name>
      <address>
        <city>Homburg</city>
        <state>Saarland</state>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Urban Sester, MD</last_name>
      <phone>0049-6841</phone>
      <phone_ext>1623541</phone_ext>
      <email>urban.sester@uks.eu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medizinische Klinik II, Aachen University</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anja Mühlfeld, MD</last_name>
      <email>amuehlfeld@ukaachen.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Charité Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lutz Liefeld, MD</last_name>
      <email>Lutz.Liefeldt@charite.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Erlangen Nürnberg</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Wiesener, MD</last_name>
      <email>michael.wiesener@uk-erlangen.de</email>
    </contact>
    <contact_backup>
      <last_name>Katharina Heller, MD</last_name>
      <email>katharina.heller@uk-erlangen.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Medizinische Klinik III, Frankfurt University</name>
      <address>
        <city>Frankfurt</city>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ingeborg A Hauser, MD</last_name>
      <phone>069 - 6301</phone>
      <phone_ext>6668</phone_ext>
      <email>i.hauser@em.uni-frankfurt.de</email>
    </contact>
    <contact_backup>
      <last_name>Tilo Freiwald, MD</last_name>
      <phone>069 - 6301</phone>
      <phone_ext>6668</phone_ext>
      <email>Tilo.Freiwald@kgu.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University Clinic of Giessen and Marburg (UKGM)</name>
      <address>
        <city>Gießen</city>
        <zip>35392</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rolf Weimer, MD</last_name>
      <phone>0641-985</phone>
      <phone_ext>42398</phone_ext>
      <email>Rolf.Weimer@innere.med.uni-giessen.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martina Koch, MD</last_name>
      <email>martina.koch@uke.de</email>
    </contact>
    <investigator>
      <last_name>Friedrich Thaiss, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Transplantationszentrum Heidelberg - Nephrologie</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Claudia Sommerer, MD</last_name>
      <phone>0049 6221 56</phone>
      <phone_ext>6110</phone_ext>
      <email>Claudia.Sommerer@med.uni-heidelberg.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Köln-Lindenthal</name>
      <address>
        <city>Köln</city>
        <zip>50935</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christine Kurschat, MD</last_name>
      <email>christine.kurschat@uk-koeln.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Lübeck</name>
      <address>
        <city>Lubeck</city>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Nitschke, MD</last_name>
      <email>Martin.Nitschke@uksh.de</email>
    </contact>
    <contact_backup>
      <last_name>Inge Derad, MD</last_name>
      <email>inge.derad@uksh.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Mainz</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jens Lutz, MD</last_name>
      <email>jens.lutz@unimedizin-mainz.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Münster</name>
      <address>
        <city>Muenster</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Barbara Suwelack, MD</last_name>
      <email>Barbara.Suwelack@ukmuenster.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Innere Medizin IV, University of Tübingen</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martina Guthoff, MD</last_name>
      <phone>0049-7071-29</phone>
      <phone_ext>83172</phone_ext>
      <email>Martina.Guthoff@med.uni-tuebingen.de</email>
    </contact>
    <contact_backup>
      <last_name>Nils Heyne, MD</last_name>
      <phone>0049-7071-29</phone>
      <phone_ext>83172</phone_ext>
      <email>nils.heyne@med.uni-tuebingen.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 15, 2015</study_first_submitted>
  <study_first_submitted_qc>December 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2015</study_first_posted>
  <last_update_submitted>January 20, 2017</last_update_submitted>
  <last_update_submitted_qc>January 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Saarland University</investigator_affiliation>
    <investigator_full_name>Martina Sester</investigator_full_name>
    <investigator_title>Univ.-Prof. Dr. Martina Sester</investigator_title>
  </responsible_party>
  <keyword>alloreactive T cell</keyword>
  <keyword>donor-specific antibody</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

